Opiate Screen, Blood from HealthLabs

The displayed price is $119 and provider pages describe self-pay, no extra visit or result charges, price protection, and cancellation rules. The generic reflex-fee clause leaves product-specific total cost and confirmation charges unresolved.

HealthLabs' category page identifies codeine, morphine, hydrocodone, and hydromorphone for the blood option, but the product page also names oxycodone without stating that it is tested. The product is not documented as a complete opioid panel.

A blood presence test can be relevant to recent opioid exposure or medication-monitoring questions. It cannot diagnose opioid use disorder or establish dose, impairment, or legal chain of custody, and the provider does not define a narrower intended use.

The product states detect and confirm, gives a broad detection window, and offers online results, but it does not show the screen method, confirmation method, units, cutoffs, reference ranges, or result format. Government guidance warns that screen results may be false positive or below threshold.

The blood route and a provider scope statement are available, but method, performing laboratory, cutoffs, confirmation procedure, and validation are not published. Government guidance makes the missing method material because standard opiate screens may miss hydrocodone, hydromorphone, or oxycodone.

The order-to-lab workflow is practical and well described, including requisition, local partner collection, no appointment language, support, and online results. State eligibility, location-specific availability, product preparation, and workplace chain of custody are not static or product-specific.

The privacy policy describes health-result handling, partner sharing, no sale, de-identified improvement, consumer rights, security, communication controls, and retention criteria. It does not give a fixed retention period or reconcile all third-party notices and post-service storage wording.

Core product, blood-route, price, workflow, network, and general scope facts are disclosed. The unresolved oxycodone wording, exact analytes, method, laboratory, cutoffs, validation, report, preparation, state availability, and regulated status materially limit auditability.